Meeting
2015 Genitourinary Cancers Symposium
Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma.
Authors
Shiven B. Patel
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Shiven B. Patel , Srinivas Kiran Tantravahi , David Gill , Austin Poole , Joseph Merriman , Julia A. Batten , David D. Stenehjem , Neeraj Agarwal
Organizations
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, University of Utah Health Care, Salt Lake City, UT, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, UT
Research Funding
No funding sources reported
Background: In the INTORSECT trial, not progression-free (PFS), but overall survival (OS) was higher with sorafenib vs. temsirolimus in 2nd setting after 1st sunitinib therapy. Here, we compare the PFS and OS between any vascular endothelial growth factor inhibitor (VEGF TKI) and mTOR inhibitors (mTORi) in 2nd setting in mRCC after progression on 1st VEGF TKI. Methods: Pts were identified from an institutional database. Survival estimates of PFS and OS were assessed from initiation of 2nd therapy by Kaplan-Meier methodology and stratified by the median PFS of the 1st therapy. Results: Of 142 pts, 66 received a VEGF TKI (n=24, 36%) or an mTORi (n=42, 64%) in 2nd setting. Pts and disease characteristics with corresponding outcomes are presented in the table. Conclusions: A trend for improved PFS and OS was found with 2nd therapy with a VEGF TKI over an mTORi. Longer OS with 2nd VEGF TKI was seen in those on 1st VEGF TKI <8 months suggesting that continued VEGF inhibition may be a reasonable strategy in these pts. Data need to be validated in a larger cohort.
| 2nd treatment | VEGF TKI (n=24) | mTORi (n=42) | All pts (N=66) | p value |
|---|---|---|---|---|
| Median survival, mos | ||||
| OS | 21.9 | 12.1 | 16.7 | 0.11 |
| 1st VEGF TKI ≥8 months | 20.4 | 19.3 | 20.4 | 0.53 |
| 1st VEGF TKI <8 months | 24.3 | 6.5 | 10.3 | 0.04 |
| PFS | 11.3 | 5.8 | 6.4 | 0.18 |
| 1st VEGF TKI ≥8 months | 11.3 | 6.4 | 9.4 | 0.29 |
| 1st VEGF TKI <8 months | 5.5 | 5.6 | 5.6 | 0.53 |
| Age, y (%) | ||||
| Median (IQR) | 61 (53-67) | 61 (54-70) | 61 (53-68) | 0.44 |
| Sex, n (%) | ||||
| Male | 14 (58) | 33 (78) | 47 (71) | 0.08 |
| Race, n (%) | ||||
| White | 21 (88) | 41 (98) | 62 (94) | 0.24 |
| Other | 3 (12) | 1 (2) | 4 (6) | |
| Histology subtype, n (%) | ||||
| Clear cell | 20 (83) | 32 (82) | 52 (83) | 0.47 |
| Papillary | 2 (8) | 3 (8) | 5 (8) | |
| Other | 2 (8) | 4 (11) | 6 (10) | |
| MSKCC, n (%) | ||||
| Favorable | 9 (39) | 11 (29) | 20 (33) | 0.21 |
| Intermediate | 14 (61) | 22 (58) | 36 (59) | |
| Poor | 0 (0) | 5 (13) | 5 (8) | |
| Heng n (%) | ||||
| Favorable | 0 (0) | 1 (3) | 1 (2) | 0.04 |
| Intermediate | 19 (83) | 20 (51) | 29 (63) | |
| Poor | 4 (17) | 18 (46) | 22 (35) | |
| 1st VEGF TKI, n (%) | ||||
| Sunitinib | 20 (83) | 40 (95) | 60 (92) | 0.21 |
| Sorafenib | 2 (8) | 1 (2) | 3 (5) | |
| Pazopanib | 2 (8) | 1 (2) | 3 (5) | |
| 2nd treatment, n (%) | ||||
| Pazopanib | 10 (42) | - | - | |
| Sorafenib | 5 (21) | - | - | |
| Axitinib | 4 (17) | - | - | |
| Sunitinib | 4 (17) | - | - | |
| Cabozantinib | 1 (4) | - | - | |
| Temsirolimus | - | 21 (50) | - | |
| Everolimus | - | 21 (50) | - |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 495)
DOI
10.1200/jco.2015.33.7_suppl.495
Abstract #
495
Poster Bd #
G23
Abstract Disclosures
Similar Abstracts
Abstract
2015 ASCO Annual Meeting
Comparative effectiveness of first-line (1st) VEGF TKI followed by second-line (2nd) therapy with either a VEGF TKI or an mTOR inhibitor in patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Shiven B. Patel
Abstract
2024 ASCO Annual Meeting
FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.
First Author: Justin Nathaniel Malinou
Abstract
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Abstract
2023 ASCO Genitourinary Cancers Symposium
Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
First Author: Yann-Alexandre Vano